CAMBRIDGE, Mass., May 12, 2026
AIRNA announced new preclinical findings at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting highlighting major advances in its RNA-editing therapeutic pipeline, including lead candidate AIR-001 for alpha-1 antitrypsin deficiency (AATD) and multiple cardiometabolic disease programs. The company reported that AIR-001 demonstrated strong in vivo RNA editing activity, achieving up to 59% precise editing in preclinical models while restoring clinically meaningful levels of functional alpha-1 antitrypsin protein. AIRNA also unveiled promising data showing that its RNA-editing platform can introduce protective cardiovascular variants capable of significantly reducing LDL cholesterol levels, reinforcing growing industry interest in next-generation RNA therapeutics and precision genetic medicine.
AIR-001 Demonstrates Strong RNA Editing in AATD Models
AIRNA’s ASGCT 2026 presentations focused heavily on AIR-001, the company’s lead RNA-editing therapeutic candidate currently being evaluated in a Phase 1 clinical trial for alpha-1 antitrypsin deficiency. AATD is a rare inherited disorder caused by mutations in the SERPINA1 gene, leading to reduced levels of functional alpha-1 antitrypsin protein and progressive lung and liver disease. AIR-001 is designed to precisely repair the disease-causing PiZ mutation at the RNA level using a subcutaneously delivered GalNAc oligonucleotide platform. According to AIRNA, the treatment achieved dose-dependent editing in mouse models, with the highest dose generating 59% RNA editing and restoring more than 40 µM of corrected functional M-AAT protein in serum. Researchers also observed approximately 70 µM total alpha-1 antitrypsin levels, supporting the therapy’s potential to address both pulmonary and hepatic complications associated with the disease.
Definium emphasized that the clinical development program is focused on addressing significant limitations associated with currently available antidepressants, many of which require several weeks before symptom improvement becomes noticeable. The company believes DT120-ODT may provide a differentiated treatment approach capable of producing faster clinical response in patients experiencing severe depressive episodes. Major depressive disorder remains one of the world’s most prevalent mental health conditions, contributing substantially to disability, reduced productivity, and increased suicide risk globally. Industry analysts estimate that more than 280 million people worldwide are affected by depression, reinforcing the urgent need for therapies capable of delivering rapid and sustained symptom relief.
The company stated that AIR-001 demonstrated improvement across several disease-related biological markers, including a more than 30-fold increase in neutrophil elastase inhibition, an important indicator linked to lung tissue protection. Longer-term preclinical studies involving bi-weekly dosing over 15 weeks showed accumulating levels of corrected protein expression, suggesting potential durability for chronic disease management. AIRNA also reported that non-human primate studies demonstrated tolerable liver exposure and favorable pharmacokinetic properties that may support dosing intervals of every eight to twelve weeks in humans. Importantly, researchers observed no significant off-target RNA edits during the studies, reinforcing the growing perception that RNA editing may offer improved precision and safety compared with some permanent gene-editing approaches.
Advertisement
Cardiometabolic RNA Editing Programs Reduce LDL Cholesterol
Beyond rare disease applications, AIRNA also presented new preclinical proof-of-concept data supporting expansion of its RNA-editing platform into cardiometabolic disorders. One of the most notable presentations involved targeting the low-density lipoprotein receptor (LDLR) pathway using RNA editing to reproduce naturally occurring protective variants associated with reduced cardiovascular risk. According to the company, its RNA-editing oligonucleotide achieved up to 70% editing efficiency in human hepatocytes and increased LDLR expression by approximately 3.5-fold. In a humanized mouse model, treatment produced a remarkable 92% reduction in LDL cholesterol levels, demonstrating the therapeutic potential of introducing beneficial genetic variants at the RNA level.
AIRNA also reported encouraging findings from its ApoB RNA-editing program, which aims to reduce cardiovascular risk without causing hepatotoxicity often associated with previous ApoB-targeting strategies. Researchers identified protective APOB variants through large-scale human genetic studies and replicated their effects using RNA editing. Preclinical studies demonstrated approximately 30% in vivo editing, resulting in a 21% reduction in ApoB protein and a 17% decrease in LDL cholesterol without evidence of liver toxicity. The company stated these results illustrate how naturally occurring protective variants identified through population genetics can be translated into scalable therapeutic approaches for broader patient populations.
AIRNA Expands Position in RNA Therapeutics Market
The ASGCT 2026 presentations reflect AIRNA’s broader strategy to position itself as a leader in the rapidly expanding RNA-editing therapeutics sector, an area attracting increasing investment across biotechnology and pharmaceutical industries. Unlike permanent DNA editing approaches, RNA editing offers the potential advantages of reversibility, repeat dosing flexibility, and reduced risk of permanent genomic alteration. AIRNA’s proprietary RESTORE+ platform uses engineered oligonucleotides to recruit endogenous ADAR enzymes capable of selectively editing RNA transcripts associated with disease-causing mutations or protective biological functions.
The company recently advanced AIR-001 into a global Phase 1 clinical trial and has continued expanding its cardiometabolic and rare disease pipeline following a successful $155 million Series B financing round earlier this year. Industry analysts believe RNA editing could emerge as one of the most competitive next-generation therapeutic modalities as companies pursue scalable alternatives to traditional gene therapy and CRISPR-based genome editing. AIRNA executives stated that the latest ASGCT data demonstrate the versatility of the company’s RNA-editing platform across both rare genetic disorders and common chronic diseases, supporting its long-term vision of delivering functional genetic medicines through precision RNA engineering.
Source: AIRNA press release
